Randomized Trialhigh evidence
Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.
Nature medicine·August 10, 2026·PMID 42575985
Why it mattersHigh-quality randomized evidence for CD20 depletion in NMOSD has been limited. This trial provides robust data supporting a new glycoengineered anti-CD20 option that may offer enhanced B-cell depletion and a favorable safety profile.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled